Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Negative Results, Disorders of the Nervous System

14-3-3θ does not protect against behavioral or pathological deficits in Alzheimer’s disease mouse models

Mary Gannon, Bing Wang, Sara Anne Stringfellow, Stephan Quintin, Itzel Mendoza, Thanushri Srikantha, A. Claire Roberts, Takashi Saito, Takaomi C. Saido, Erik Roberson and Talene A. Yacoubian
eNeuro 13 June 2022, ENEURO.0368-21.2022; https://doi.org/10.1523/ENEURO.0368-21.2022
Mary Gannon
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mary Gannon
Bing Wang
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Anne Stringfellow
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
2University of South Alabama College of Medicine, Mobile, AL 36688
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan Quintin
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
3Medical Scientist Training Program, University of Florida, Gainesville, FL 32611
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itzel Mendoza
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanushri Srikantha
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Claire Roberts
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Saito
4RIKEN Center for Brain Science, Saitama 351-0198, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takaomi C. Saido
4RIKEN Center for Brain Science, Saitama 351-0198, Japan
5Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduates School of Medical Sciences, Nagaya, 467-8601, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik Roberson
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erik Roberson
Talene A. Yacoubian
1Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL 35294
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Alzheimer’s disease (AD) is characterized by progressive cognitive impairment associated with synaptic dysfunction and dendritic spine loss and the pathological hallmarks of amyloid beta (Aβ) plaques and hyperphosphorylated tau tangles. 14-3-3 proteins are a highly conserved family of proteins whose functions include regulation of protein folding, neuronal architecture, and synaptic function. Additionally, 14-3-3s interact with both Aβ and tau, and reduced levels of 14-3-3s have been shown in the brains of AD patients and in AD mouse models. Here we examine the neuroprotective potential of the 14-3-3θ isoform in AD models. We demonstrate that 14-3-3θ overexpression is protective and 14-3-3θ inhibition is detrimental against oligomeric Aβ-induced neuronal death in primary cortical cultures. Overexpression of 14-3-3θ using an adeno-associated viral vector failed to improve performance on behavioral tests, improve Aβ pathology, or affect synaptic density in the J20 AD mouse model. Similarly, crossing a second AD mouse model, the AppNL-G-F knock-in (APP KI) mouse, with 14-3-3θ transgenic mice failed to rescue behavioral deficits, reduce Aβ pathology, or impact synaptic density in the APP KI mouse model. 14-3-3θ is likely partially insolubilized in the APP models, as demonstrated by proteinase K digestion. These findings do not support increasing 14-3-3θ expression as a therapeutic approach for AD.

Significance Statement

Despite being the most common form of neurodegeneration, effective treatments for Alzheimer’s disease (AD) remain elusive and therefore novel therapeutic targets are needed. 14-3-3 proteins, a highly conserved family of chaperone proteins involved in regulating synaptic function and neuronal architecture, are reduced in human AD patients, making them a promising novel target. In this study, we examined the effects of increasing the 14-3-3θ isoform in AD models. We observed that 14-3-3θ overexpression reduces oligomeric Aβ toxicity in cortical cultures. However, increasing the 14-3-3θ expression in two different AD mouse models failed to rescue behavioral or pathological phenotypes, indicating a more complicated relationship between 14-3-3s and AD.

  • ß-amyloid
  • 14-3-3
  • Alzheimer’s disease
  • cortex
  • hippocampus
  • mouse model

Footnotes

  • The authors have no conflicts of interest.

  • This study was supported by NIH R01 NS088533 (TAY), R01 NS112203 (TAY), the Alzheimer’s of Central Alabama (TAY), and the UAB School of Medicine (AMC21 Multi-R01 Pilot Grant; TAY).

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

Back to top
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
14-3-3θ does not protect against behavioral or pathological deficits in Alzheimer’s disease mouse models
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
View Full Page PDF
Citation Tools
14-3-3θ does not protect against behavioral or pathological deficits in Alzheimer’s disease mouse models
Mary Gannon, Bing Wang, Sara Anne Stringfellow, Stephan Quintin, Itzel Mendoza, Thanushri Srikantha, A. Claire Roberts, Takashi Saito, Takaomi C. Saido, Erik Roberson, Talene A. Yacoubian
eNeuro 13 June 2022, ENEURO.0368-21.2022; DOI: 10.1523/ENEURO.0368-21.2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
14-3-3θ does not protect against behavioral or pathological deficits in Alzheimer’s disease mouse models
Mary Gannon, Bing Wang, Sara Anne Stringfellow, Stephan Quintin, Itzel Mendoza, Thanushri Srikantha, A. Claire Roberts, Takashi Saito, Takaomi C. Saido, Erik Roberson, Talene A. Yacoubian
eNeuro 13 June 2022, ENEURO.0368-21.2022; DOI: 10.1523/ENEURO.0368-21.2022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • ß-amyloid
  • 14-3-3
  • Alzheimer’s disease
  • Cortex
  • hippocampus
  • mouse model

Responses to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Negative Results

  • Closed-Loop Acoustic Stimulation Enhances Sleep Oscillations But Not Memory Performance
  • Cyfip1 Haploinsufficiency Does Not Alter GABAA Receptor δ-Subunit Expression and Tonic Inhibition in Dentate Gyrus PV+ Interneurons and Granule Cells
  • Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
Show more Negative Results

Disorders of the Nervous System

  • Closed-Loop Acoustic Stimulation Enhances Sleep Oscillations But Not Memory Performance
  • Cyfip1 Haploinsufficiency Does Not Alter GABAA Receptor δ-Subunit Expression and Tonic Inhibition in Dentate Gyrus PV+ Interneurons and Granule Cells
  • Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.